about
Meta-analysis of early nonmotor features and risk factors for Parkinson diseaseImpact of newer pharmacological treatments on quality of life in patients with Parkinson's diseaseDisability Rating Scales in Parkinson's Disease: Critique and Recommendations.A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's diseasePREDICT-PD: identifying risk of Parkinson's disease in the community: methods and baseline resultsStudy protocol: Insight 46 - a neuroscience sub-study of the MRC National Survey of Health and Development.Estimating the causal influence of body mass index on risk of Parkinson disease: A Mendelian randomisation study.Dystonia rating scales: critique and recommendationsReview of diagnostic instruments for the restless legs syndrome/Willis-Ekbom Disease (RLS/WED): critique and recommendations.Review of quality of life instruments for the restless legs syndrome/Willis-Ekbom Disease (RLS/WED): critique and recommendationsDepression rating scales in Parkinson's disease: critique and recommendations.The role of cognitive-behavioural therapy for patients with depression in Parkinson's disease.Adolescent and adult children of parents with Parkinson's disease: incorporating their needs in clinical guidelines.Psychiatric aspects of Parkinson's disease--an update.Entacapone in the treatment of Parkinson's disease.Estimated life expectancy of Parkinson's patients compared with the UK population.Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism.Quality of life and depression in Parkinson's disease.The natural history of multiple system atrophy: a prospective European cohort studyMapping the EQ-5D index by UPDRS and PDQ-8 in patients with Parkinson's disease.Genetic comorbidities in Parkinson's disease.Neuropsychiatric symptoms in Parkinson's disease.Refinement and validation of the Parental Illness Impact Scale.Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations.Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease.Scales to assess sleep impairment in Parkinson's disease: critique and recommendations.Hyperkinetic psychogenic movement disorders.The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension.Health-related quality-of-life scales in Parkinson's disease: critique and recommendations.Wearing-off scales in Parkinson's disease: critique and recommendations.Testing an aetiological model of visual hallucinations in Parkinson's disease.Psychosis, apathy, depression and anxiety in Parkinson's disease.Health-related quality of life in Gilles de la Tourette syndrome: a decade of researchMeasurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease.Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life.Task force report: scales for screening and evaluating tremor: critique and recommendations.Time trends in incidence of Parkinson's disease diagnosis in UK primary care.What is the clinically relevant change on the ADAS-Cog?Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers).New clinical trials for nonmotor manifestations of Parkinson's disease.
P50
Q22252935-E96D225D-7D38-45E6-A78D-403E3B260C23Q28283547-12C94468-0E07-4754-B222-BB0F830AA7C4Q30250276-77D7B67C-34FD-4D93-8892-B1DA1F0D45AFQ30482570-FCF202F9-4084-4621-8936-BBF2D7954052Q30564071-F6CBA2AB-09E8-4E9E-AC5C-1AA4EC517C98Q33576727-994D3C06-E70A-43A1-9553-6A1B31EF89F9Q33793017-6D91DFA9-8EAE-4687-AC5E-D5527BAD1842Q34393230-7975AB62-DD20-493D-A50C-1902B85724FCQ34542952-47859337-A174-4D95-8A79-813FF71AD4E0Q34542958-1BAC6412-9521-4399-AA2C-3E0975979CAFQ34578187-AD73A7DE-F62B-4F6C-9399-0B11D7E3A936Q35101458-05713C6F-9F99-4634-8710-AE6888AB08EAQ35101526-55EE0E6C-2717-48BC-A5C8-A6E6243FEC91Q35838935-1A348B21-1391-47E8-A095-BEBD42CC352DQ36134208-77F84270-39F0-4755-8E12-B3D50CEA294AQ36172639-ED3F18F9-F191-442E-8739-CAF36F26C6F7Q36424540-3906B19B-EFEF-4DB3-9465-67911C815F37Q36517106-E980EF24-278C-49F0-814A-7068F274E608Q36637012-0F38F258-8062-43C0-8F1F-06C930BB4D3AQ36869443-2CD429B9-6C5C-46EF-B7EC-30CAD8FABEC4Q37464009-78F263BD-F497-4A75-83D5-FCB896EB888DQ37600783-303B0295-FBA4-4309-A22E-1E1E20753086Q37638890-2A23628D-6AE4-46A9-BA63-1938053A997BQ37716740-48AAA664-BF9E-4996-ADF6-88A869269D38Q37749714-0385B499-5498-4A48-BEC7-F46A41F4C363Q37798777-6335F5C1-3074-434C-B42C-0BCD9F445DC5Q37865688-A804E5E1-8AE3-426B-AB67-1D3458435CE9Q37872684-E931256B-22DA-4504-992B-8ADFCF547688Q37898591-281EEDDA-24CB-4C04-9CBC-4C9F02132D8CQ37903795-68079FCB-6A07-4799-B648-CAE0C87A2BE3Q37932878-53F8FA4B-4C03-4413-A4C1-2E6C73C10F76Q37975845-291FC2BD-9E54-4FC7-A8D6-FA5D0F5D9770Q38063070-029B0A36-17C7-464C-A1F1-C5C775CD3577Q38122127-2E5B2CAD-98FD-4B25-B320-8BB6ADED0478Q38128451-9DD31747-F8EB-49CA-A91C-A4C2DAB745CDQ38137916-8AEE3DB2-CDCA-467B-86C6-510620ACEA4AQ38428462-5345BFD7-EBE3-439A-9A05-0562E1D6DDB1Q38482318-55B70473-DAF3-4877-9303-695CDF1D61AEQ38564776-082EE47F-134E-4E09-AFCC-3D41D5D37753Q38587090-561C034B-DA9A-4F89-BD41-4BB0A538C0E2
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Anette Schrag
@ast
Anette Schrag
@en
Anette Schrag
@es
Anette Schrag
@nl
Anette Schrag
@sl
type
label
Anette Schrag
@ast
Anette Schrag
@en
Anette Schrag
@es
Anette Schrag
@nl
Anette Schrag
@sl
prefLabel
Anette Schrag
@ast
Anette Schrag
@en
Anette Schrag
@es
Anette Schrag
@nl
Anette Schrag
@sl
P214
P1053
B-4181-2011
P106
P21
P214
P31
P3829
P496
0000-0002-9872-6680
P734
P735
P7859
lccn-n2011186762